OPEN END TURBO LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 12:16:31 25/06/2024 pm IST | ||
| 11.14 EUR / 11.25 EUR | +0.77% |
|
| Current month | +18.95% | ||
| 1 month | +17.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 11.11 | +4.22% |
| 21/24/21 | 10.66 | -0.65% |
| 20/24/20 | 10.73 | +4.79% |
| 19/24/19 | 10.24 | -1.73% |
| 18/24/18 | 10.42 | -5.87% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB7J5C |
| ISIN | DE000MB7J5C6 |
| Date issued | 15/06/2023 |
| Strike | 357.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.02 € |
|---|---|
| Lowest since issue | 0.94 € |
| Spread | 0.2 € |
| Spread % | 1.78% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
464
USD
Spread / Average Target
-2.31%
- Stock Market
- Certificates
- Certificat
